LRP1 promotes synthetic phenotype of pulmonary artery smooth muscle cells in pulmonary hypertension

Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1604-1616. doi: 10.1016/j.bbadis.2019.03.012. Epub 2019 Mar 22.

Abstract

Pulmonary hypertension (PH) is characterized by a thickening of the distal pulmonary arteries caused by medial hypertrophy, intimal proliferation and vascular fibrosis. Low density lipoprotein receptor-related protein 1 (LRP1) maintains vascular homeostasis by mediating endocytosis of numerous ligands and by initiating and regulating signaling pathways. Here, we demonstrate the increased levels of LRP1 protein in the lungs of idiopathic pulmonary arterial hypertension (IPAH) patients, hypoxia-exposed mice, and monocrotaline-treated rats. Platelet-derived growth factor (PDGF)-BB upregulated LRP1 expression in pulmonary artery smooth muscle cells (PASMC). This effect was reversed by the PDGF-BB neutralizing antibody or the PDGF receptor antagonist. Depletion of LRP1 decreased proliferation of donor and IPAH PASMC in a β1-integrin-dependent manner. Furthermore, LRP1 silencing attenuated the expression of fibronectin and collagen I and increased the levels of α-smooth muscle actin and myocardin in donor, but not in IPAH, PASMC. In addition, smooth muscle cell (SMC)-specific LRP1 knockout augmented α-SMA expression in pulmonary vessels and reduced SMC proliferation in 3D ex vivo murine lung tissue cultures. In conclusion, our results indicate that LRP1 promotes the dedifferentiation of PASMC from a contractile to a synthetic phenotype thus suggesting its contribution to vascular remodeling in PH.

Keywords: Cell proliferation; Low density lipoprotein receptor-related protein 1; Pulmonary hypertension; Smooth muscle cell phenotype; β1-integrin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / genetics
  • Actins / metabolism
  • Adult
  • Animals
  • Antibodies, Neutralizing / pharmacology
  • Becaplermin / antagonists & inhibitors
  • Becaplermin / genetics*
  • Becaplermin / metabolism
  • Case-Control Studies
  • Cell Dedifferentiation / genetics*
  • Cell Proliferation / drug effects
  • Collagen Type I / genetics
  • Collagen Type I / metabolism
  • Disease Models, Animal
  • Familial Primary Pulmonary Hypertension / chemically induced
  • Familial Primary Pulmonary Hypertension / genetics*
  • Familial Primary Pulmonary Hypertension / metabolism
  • Familial Primary Pulmonary Hypertension / pathology
  • Female
  • Fibronectins / genetics
  • Fibronectins / metabolism
  • Gene Expression Regulation
  • Homeostasis / genetics
  • Humans
  • Integrin beta1 / genetics
  • Integrin beta1 / metabolism
  • Low Density Lipoprotein Receptor-Related Protein-1 / antagonists & inhibitors
  • Low Density Lipoprotein Receptor-Related Protein-1 / genetics*
  • Low Density Lipoprotein Receptor-Related Protein-1 / metabolism
  • Male
  • Mice
  • Middle Aged
  • Monocrotaline / administration & dosage
  • Myocytes, Smooth Muscle / drug effects
  • Myocytes, Smooth Muscle / metabolism*
  • Myocytes, Smooth Muscle / pathology
  • Nuclear Proteins / genetics
  • Nuclear Proteins / metabolism
  • Pulmonary Artery / drug effects
  • Pulmonary Artery / metabolism
  • Pulmonary Artery / pathology
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Rats
  • Receptors, Platelet-Derived Growth Factor / genetics
  • Receptors, Platelet-Derived Growth Factor / metabolism
  • Signal Transduction
  • Tissue Culture Techniques
  • Trans-Activators / genetics
  • Trans-Activators / metabolism

Substances

  • ACTA2 protein, human
  • Actins
  • Antibodies, Neutralizing
  • Collagen Type I
  • Fibronectins
  • Integrin beta1
  • LRP1 protein, human
  • Low Density Lipoprotein Receptor-Related Protein-1
  • Nuclear Proteins
  • RNA, Small Interfering
  • Trans-Activators
  • myocardin
  • Becaplermin
  • Monocrotaline
  • Receptors, Platelet-Derived Growth Factor